A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

@article{Pienta1997API,
  title={A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.},
  author={Kenneth J. Pienta and Bruce G. Redman and Rajesh Bandekar and Myla Strawderman and Kemp B. Cease and Peg Esper and H. Srinivasa Naik and David Cameron-5 Smith},
  journal={Urology},
  year={1997},
  volume={50 3},
  pages={401-6; discussion 406-7}
}
OBJECTIVES We previously demonstrated that the combination of oral estramustine (15 mg/kg/day) and oral etoposide (50 mg/m2/day) is effective first-line therapy for the treatment of hormone refractory prostate cancer. We initiated a new Phase II trial utilizing a lower dose of estramustine (10 mg/kg/day) and allowing previous chemotherapy treatment. METHODS Estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) were administered orally for 21 of 28 days. Sixty-two patients were enrolled… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2005

Similar Papers

Loading similar papers…